WEQL yields 1000000.00% · ABBV yields 3.06%● Live data
📍 WEQL pulled ahead of the other in Year 1
Combined, WEQL + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of WEQL + ABBV for your $10,000?
WellQuest Medical & Wellness Corporation provides an integrated medical delivery site with family physician healthcare, preventive/wellness, and medical skin-care services. It operates medical center that provides physician-directed medical service for families and businesses, which offers a range of medical care for adults and children with digital diagnostic tests, including laboratory, X-ray, EKG, and others. The company also offers various immunizations for all ages; and weight loss program, nutritional counseling, allergy testing, fitness consulting, hormone therapy, and therapeutic massage services, as well as designs personalized treatment plans. In addition, it manufactures and sells heart support; bone and joint support; stress, mood, and sleep support; immune support; and vitamins and minerals capsules. Further, the company provides aesthetic services, which include medical spa, laser skin renewal, botox and dermal fillers, skin print technology, facials and derma sweep, Glo minerals, and teeth whitening services. Additionally, it offers corporate wellness, occupational and executive health, genetic testing, and tobacco cessation services. The company was formerly known as HQHealthQuest Medical & Wellness Centers, Ltd. and changed its name to WellQuest Medical & Wellness Corporation in April 2008. WellQuest Medical & Wellness Corporation was incorporated in 2004 and is based in Bentonville, Arkansas.
Full WEQL Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.